TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21118281

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg intravenously)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19489487

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Fenglong (ST 40) with parameters: 50 Hz, 1 mA for TG type (20 min, twice/week); 100 Hz, 1 mA for CHO type (30 min, thrice/week); same as CHO for LDL-C type; alternating methods for mixing type.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Xuezhikang capsule, 2 capsules twice daily for 11 weeks.
Number of subjects: 204
Study: 16479346

Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy with submucosal dissection
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy
Number of subjects: 84
Study: 14749658

Group type: EXPERIMENTAL
Intervention: Diet plus resistance exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 32
Study: 11322472

Group type: EXPERIMENTAL
Intervention: Treadmill training (15 sessions with handrail support)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional over-ground gait training (15 sessions)
Number of subjects: 25
Study: 9160363

Group type: EXPERIMENTAL
Intervention: Fingertip temperature monitoring during rewarming
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nasopharyngeal temperature monitoring during rewarming
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Arterial blood temperature monitoring during rewarming
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall temperature monitoring during rewarming
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fingertip temperature as a monitor for cerebral temperature
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Further body warming
Number of subjects: 14
Study: 8192275

Group type: EXPERIMENTAL
Intervention: 2 grams of oral vitamin C for one month
Number of subjects: 124
Study: 3285763

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29689025

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab + subthreshold micropulse laser photocoagulation (IVR + SMLP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) monotherapy
Number of subjects: 46
Study: 28035912

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound with thumb spica splint
Number of subjects: 30

Group type: COMPARATOR
Intervention: Therapeutic ultrasound alone
Number of subjects: 30
Study: 26168752

Group type: EXPERIMENTAL
Intervention: RO (external ring opened, hernial sac twisted and doubly ligated)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: ST (hernial sac twisted and doubly ligated without opening the ring)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: DL (double ligation of hernial sac without ring opening nor twisted)
Number of subjects: 428

Group type: COMPARATOR
Intervention: SL (single ligation of hernial sac with neither ring opening nor sac twisting)
Number of subjects: 428
Study: 23892902

Group type: EXPERIMENTAL
Intervention: Long-bout group (30 min × 1) 3 d per week
Number of subjects: 23

Group type: COMPARATOR
Intervention: Short-bouts group (10 min × 3) 3 d per week
Number of subjects: 23
Study: 22049798

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d for 30 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18497524

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 73

Group type: COMPARATOR
Intervention: Travoprost
Number of subjects: 73
Study: 16527402

Group type: EXPERIMENTAL
Intervention: Baseline health-state-related variables
Number of subjects: 148

Group type: COMPARATOR
Intervention: Patients without disability
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Predictive factors identified
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Replacement of baseline health-state-related measures with post-treatment measures
Number of subjects: 148
Study: 14527106

Group type: EXPERIMENTAL
Intervention: Protocol-driven care
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 172
Study: 10908079

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8612391

Group type: EXPERIMENTAL
Intervention: 200 mg entacapone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 mg moclobemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of entacapone and moclobemide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Entacapone and moclobemide (combined)
Number of subjects: 12
Study: 1599113

Group type: COMPARATOR
Intervention: 1% methohexital in saline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1% methohexital in lipid emulsion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.1% methohexital in saline
Number of subjects: 24
Study: 6443775

Group type: EXPERIMENTAL
Intervention: Cefsulodin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Reference antibiotics (gentamicin, tobramycin, amikacin, or ticarcillin)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Reference antibiotics
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cefsulodin or reference antibiotics
Number of subjects: 67
Study: 31913519

Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg
Number of subjects: 1230

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1230
Study: 30029719

Group type: COMPARATOR
Intervention: Localized heat
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral hydration
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 39
Study: 27170538

Group type: EXPERIMENTAL
Intervention: Aerobic exercise with cycle ergometer
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 34
Study: 25630248

Group type: EXPERIMENTAL
Intervention: Moderate Resistance (MR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High Resistance (HR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 23047792

Group type: EXPERIMENTAL
Intervention: Life review program
Number of subjects: 80
Study: 21415134

Group type: EXPERIMENTAL
Intervention: Combination antithrombotic therapy (subcutaneous idraparinux 2.5 mg weekly + antiplatelet therapy)
Number of subjects: 4576

Group type: COMPARATOR
Intervention: Anticoagulation therapy only (dose-adjusted vitamin K antagonists)
Number of subjects: 4576

Group type: EXPERIMENTAL
Intervention: Combination antithrombotic therapy
Number of subjects: 4576
Study: 18502255

Group type: EXPERIMENTAL
Intervention: UV irradiation (suberythemal doses, twice weekly for 12 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no UV irradiation)
Number of subjects: 51
Study: 16553686

Group type: EXPERIMENTAL
Intervention: Customized exercise programme (12-month programme of cardiorespiratory, stretching, muscle-strengthening and relaxation exercises, 2 sessions per week, total of 3 hours weekly)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 15220882

Group type: EXPERIMENTAL
Intervention: Guided self‐training program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Functional brace
Number of subjects: 60
Study: 11061158

Group type: EXPERIMENTAL
Intervention: Implementation of an outpatient practice guideline
Number of subjects: 0
Study: 12206032

Group type: EXPERIMENTAL
Intervention: Colgate Optimized Stannous Fluoride (COSF) dentifrice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 0
Study: 8446047

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hypocaloric glucose infusion
Number of subjects: 26
Study: 3097383

Group type: EXPERIMENTAL
Intervention: Intravenous 100 micrograms of human corticotropin-releasing factor
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31613387

Group type: EXPERIMENTAL
Intervention: Dance-exercise intervention (DI)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Life as usual (LAU)
Number of subjects: 62
Study: 29423501

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 26787029

Group type: EXPERIMENTAL
Intervention: 1000-centistoke silicone oil
Number of subjects: 85

Group type: COMPARATOR
Intervention: 5000-centistoke silicone oil
Number of subjects: 85
Study: 24057928

Group type: EXPERIMENTAL
Intervention: SEQ-FLUOX (fluoxetine 20mg, starting 8 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Number of subjects: 216

Group type: COMPARATOR
Intervention: ST-FLUOX (fluoxetine 20mg, starting 2 weeks before quit date and continuing for 8 weeks after quit date + TNP)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: SEQ-FLUOX
Number of subjects: 216
Study: 22993923

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined anaesthesia (general + epidural)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined anaesthesia (general + spinal)
Number of subjects: 120
Study: 20013016

Group type: EXPERIMENTAL
Intervention: Micafungin therapy
Number of subjects: 1070
Study: 18595990

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 400 mug of cobalamin
Number of subjects: 107

Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 107
Study: 16021395

Group type: EXPERIMENTAL
Intervention: Early chest tube removal
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional chest tube management
Number of subjects: 93
Study: 11413538

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (vincristine, actinomycin-D, cyclophosphamide - VAC)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Surgery plus radiotherapy (RT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Biopsy plus RT
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Biopsy without RT
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IRS-III/IV treatments
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IRS-I/II treatments
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Age 1-9 years at diagnosis
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Local therapy (surgery and RT)
Number of subjects: 151
Study: 9001297

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 50 microg every 12 h
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral theophylline (individually dose‐titrated sustained-release)
Number of subjects: 15
Study: 8394627

Group type: EXPERIMENTAL
Intervention: Erythromycin (0.5 g b.i.d.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Metronidazole (0.4 g b.i.d.)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months
Number of subjects: 34
Study: 3318859

Group type: EXPERIMENTAL
Intervention: Synthaderm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (non-adhesive dressing)
Number of subjects: 0
Study: 31325318

Group type: EXPERIMENTAL
Intervention: Biologics treatment
Number of subjects: 515
Study: 26583455

Group type: EXPERIMENTAL
Intervention: Habit reversal training (HRT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 21
Study: 27118206

Group type: EXPERIMENTAL
Intervention: Increase of daily GH dose (IGF-1 target level of 1 to 2 SDS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Decrease of daily GH dose (IGF-1 target level of -2 to -1 SDS)
Number of subjects: 32
Study: 24267731

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Metformin 1000 mg/day
Number of subjects: 96
Study: 22403987

Group type: COMPARATOR
Intervention: Positive control toothpaste containing 8.0% arginine and 1450 ppm fluoride as sodium monofluorophosphate (MFP) in a calcium carbonate base
Number of subjects: 150

Group type: COMPARATOR
Intervention: Positive control toothpaste containing 8.0% arginine and 1450 ppm fluoride as MFP in a calcium carbonate base
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Test toothpaste containing 8% strontium acetate and 1040 ppm fluoride as NaF in a silica base
Number of subjects: 150

Group type: COMPARATOR
Intervention: Negative control toothpaste containing 1100 ppm fluoride as NaF in a silica base
Number of subjects: 150
Study: 19298639

Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) administration of darbepoetin alfa
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) administration of darbepoetin alfa
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both s.c. and i.v. administration of darbepoetin alfa
Number of subjects: 65
Study: 16808591

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (3M ESPE, Seefeld, Germany)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Transbond XT (3M Unitex, Monrovia, Calif)
Number of subjects: 40
Study: 14688694

Group type: EXPERIMENTAL
Intervention: Intra-aortic filtration
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control
Number of subjects: 582
Study: 11055816

Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (walking)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (steering a wheelchair)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blindfolded locomotion (verbal ordering a second person pushing their wheelchair)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (experts in other non-gymnastic sports)
Number of subjects: 8
Study: 9242894

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8392826

Group type: EXPERIMENTAL
Intervention: Granisetron tablet (2 mg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 3107546

Group type: EXPERIMENTAL
Intervention: Prazosin therapy (1 to 8 mg/day for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol therapy (20 to 240 mg/day for 8 weeks)
Number of subjects: 20
Study: 29220885

Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol‐epoetin β (MEB)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Combination therapy with disease‐modifying drugs and MEB
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Combined therapy using MEB medication and iron
Number of subjects: 208
Study: 26969836

Group type: EXPERIMENTAL
Intervention: Lettuce juice beverage containing approximately 200 mg nitrate per day (test)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo beverage devoid of nitrate (control)
Number of subjects: 44
Study: 25621588

Group type: EXPERIMENTAL
Intervention: Self-forgiveness workbook intervention (6-hour self-directed workbook)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 204
Study: 23041328

Group type: EXPERIMENTAL
Intervention: Real-time optical biopsy analysis of polyps with narrow band imaging (NBI)
Number of subjects: 12
Study: 20627979

Group type: EXPERIMENTAL
Intervention: 225 IU starting dose of recombinant FSH (r‐FSH)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 150 IU starting dose of recombinant FSH (r‐FSH)
Number of subjects: 32
Study: 19120955

Group type: EXPERIMENTAL
Intervention: New rating form with prompts, free-text comments, behavioral anchors, and fewer scoring levels
Number of subjects: 80

Group type: COMPARATOR
Intervention: Current American Board of Internal Medicine Mini-CEX form
Number of subjects: 80
Study: 21775910

Group type: EXPERIMENTAL
Intervention: 530 mg of concentrated valerian extract twice a day for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo twice a day for 4 weeks
Number of subjects: 100
Study: 16238858

Group type: EXPERIMENTAL
Intervention: Threat condition (reading about symptoms and consequences of frostbite)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Reassurance condition (reading about the safety of the CPT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control condition (no orienting passage)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Threat condition
Number of subjects: 121
Study: 12898824

Group type: EXPERIMENTAL
Intervention: Coping strategies among patients with allergic diseases
Number of subjects: 0
Study: 9855317

Group type: EXPERIMENTAL
Intervention: Fasting conditions (PZA 30 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Antacids (PZA 30 mg/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-fat meal (PZA 30 mg/kg)
Number of subjects: 14
Study: 7978423

Group type: COMPARATOR
Intervention: Atracurium (A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vecuronium (V)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mivacurium (M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atracurium with Mivacurium (cAM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium with Mivacurium (cVM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 60
Study: 3289717

Group type: EXPERIMENTAL
Intervention: Alprazolam (2.4 mg average daily dose)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Amitriptyline hydrochloride (135 mg average daily dose)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 130
Study: 30115104

Group type: EXPERIMENTAL
Intervention: At-the-margins analysis
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Inside-the-table analysis
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Bayesian vetted bootstrap
Number of subjects: 2252
Study: 27632863

Group type: EXPERIMENTAL
Intervention: Static stretching (SS) program performed 3 times weekly for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 26202165

Group type: EXPERIMENTAL
Intervention: Group II (BIS 40 < BIS ≤ 50)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Group I (BIS 30 < BIS ≤ 40)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Group III (BIS 50 < BIS ≤ 60)
Number of subjects: 192
Study: 23041618

Group type: EXPERIMENTAL
Intervention: Small Changes (SC) approach
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: SC phone
Number of subjects: 481

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 481
Study: 20939080

Group type: EXPERIMENTAL
Intervention: SNP rs3943552 T allele in the GLI2 gene
Number of subjects: 327
Study: 18979972

Group type: EXPERIMENTAL
Intervention: 8-week smoking cessation program with optimistic expectations
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8-week smoking cessation program with modest expectations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-week smoking cessation program
Number of subjects: 0
Study: 16303228

Group type: EXPERIMENTAL
Intervention: Screen-and-treat program for vaginal infection
Number of subjects: 2058

Group type: COMPARATOR
Intervention: Control group (no screen-and-treat program)
Number of subjects: 2058
Study: 12660517

Group type: EXPERIMENTAL
Intervention: Conversion from cyclosporine A (CsA) to azathioprine (AZA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Conversion from cyclosporine A (CsA) to mycophenolate mofetil (MMF)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group without AR
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA) therapy
Number of subjects: 29
Study: 11045249

Group type: EXPERIMENTAL
Intervention: OBF tonograph
Number of subjects: 102

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 102

Group type: COMPARATOR
Intervention: ECG pulse rate
Number of subjects: 102
Study: 8853082

Group type: EXPERIMENTAL
Intervention: Propofol-sufentanil
Number of subjects: 329

Group type: COMPARATOR
Intervention: Sufentanil-midazolam
Number of subjects: 329
Study: 1381210

Group type: EXPERIMENTAL
Intervention: 1000 mg per day of medroxyprogesterone acetate (MPA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chemotherapy regimen (cisplatin, 5‐fluorouracil, methotrexate, bleomycin, vincristine)
Number of subjects: 21
Study: 6361006

Group type: EXPERIMENTAL
Intervention: Quazepam 30 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 29225060

Group type: EXPERIMENTAL
Intervention: Posterior robot‐assisted radical prostatectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Anterior robot‐assisted radical prostatectomy
Number of subjects: 120
Study: 26996107

Group type: EXPERIMENTAL
Intervention: 25000 IU/d retinyl palmitate (RP) for 6 months followed by 10000 IU/d RP for another 6 months
Number of subjects: 101
Study: 25157723

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood pressure combined with an individualized self-titration algorithm.
Number of subjects: 552

Group type: COMPARATOR
Intervention: Usual care (routine blood pressure measurement and adjustment of medication if necessary).
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Self-monitoring with self-titration of antihypertensive medication.
Number of subjects: 552

Group type: COMPARATOR
Intervention: Usual care.
Number of subjects: 552
Study: 23737510

Group type: EXPERIMENTAL
Intervention: mirtazapine 30 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: mirtazapine 15 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 20627502

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation with low-intensity exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 17492340

Group type: EXPERIMENTAL
Intervention: Triple therapy (7 sessions of IPL, 9 sessions of low intense diode light, and biostimulation by drugs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monotherapy (7 sessions of IPL only)
Number of subjects: 100
Study: 17213792

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg per os on demand for 3 months (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg per os on weekly fixed days (Monday‐Wednesday‐Friday) for 3 months (Group B)
Number of subjects: 20